Search
for
Sort by
Research 31–60 of 1000+
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Alopecia areata following COVID-19 vaccine: a systematic review
- A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
- Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- Image 1_Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata.tif
- Alopecia Areata Possibly Secondary to COVID-19 Vaccine
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- Post-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management.
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
- 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms
- Supplementary file 1_Research progress in the treatment of non-scarring alopecia: mechanism and treatment.docx
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Additional file 10 of Time-course RNA-seq analysis reveals stage-specific and melatonin-triggered gene expression patterns during the hair follicle growth cycle in Capra hircus
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1